Increasing evidence suggests that brain tumors arise from the transformation of neural stem/precursor/progenitor cells. Much current research on human brain tumors is focused on the stem-like properties of glioblastoma. Here we show that anaplastic lymphoma kinase (ALK) and its ligand pleiotrophin are required for the self-renewal and tumorigenicity of glioblastoma stem cells (GSCs). Furthermore, we demonstrate that pleiotrophin is transactivated directly by SOX2, a transcription factor essential for the maintenance of both neural stem cells and GSCs. We speculate that the pleiotrophin-ALK axis may be a promising target for the therapy of glioblastoma.
INTRODUCTION
Glioblastoma is one of the most aggressive human cancers with a median survival of around 1 year. 1 Increasing evidence suggests that glioblastoma may arise from the transformation of neural stem/precursor/progenitor cells. 2 Consistent with this idea, glioblastoma cells cultured in serum-free media, which favor the growth of neural stem cells (NSCs), maintain stem-like properties and tumorigenicity. 3 However, when grown in the presence of serum, they undergo irreversible differentiation and lose their tumorigenicity. 3 This finding raises the possibility that differentiation therapy might be effective for glioblastoma. 4 Almost all cell proliferative signaling involves phosphotransfer cascades, and accordingly protein kinases have been intensely pursued as drug targets. Indeed, a number of small-molecule inhibitors and antibodies targeting kinases are currently being used for cancer treatment. 5 Therefore, one approach to developing differentiation-inducing therapies for glioblastoma would be to identify kinases that regulate their stem-like properties.
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that is bound by the growth factor pleiotrophin or the closely related midkine. 6, 7 ALK was initially discovered as a protein fused to nucleophosmin (NPM) in an anaplastic large cell lymphoma (ALCL). This fusion was shown to cause the ligand-independent autophosphorylation and activation of ALK. Studies using mouse models further showed that this NPM-ALK fusion is a primary driver of oncogenesis in ALCL. 8 Moreover, oncogenic fusions or mutations of ALK have also been described in various other cancers, including inflammatory myofibroblastic tumors, non-small cell lung cancer (NSCLC), diffuse large B-cell lymphoma, squamous cell carcinoma of the esophagus and neuroblastoma. 7 Importantly, the ALK inhibitor crizotinib has recently been approved for the treatment of ALK-positive NSCLC. 9, 10 In addition, an anti-ALK antibody has been shown to repress the invasive capacity of the glioblastoma cell line U87 (Stylianou et al. 11 ).
The Sry-related transcription factor SOX2 was identified as a partner of Oct3/4 in embryonic stem cells (ESCs) and is known to be essential for pluripotent cell development. [12] [13] [14] SOX2 is also expressed in NSCs and has an important role in neural development and homeostasis of the adult central nervous system. 14, 15 On the other hand, it has also been shown that SOX2 is overexpressed in glioblastoma. 16 Furthermore, it has been reported that knockdown of SOX2 by RNA interference (RNAi) suppresses the tumorigenicity of glioblastoma stem cells (GSCs) xenografted into immunodeficient mice. 17 In the present study, we show that the pleiotrophin-ALK axis is activated by SOX2 and is required for the self-renewal and tumorigenicity of GSCs.
RESULTS
ALK and its ligand pleiotrophin are required for the self-renewal and stem-like properties of GSCs We established four GSC lines under serum-free conditions, GB2-5, and found that they are of the proneural type. 18, 19 These cell lines exhibited enrichment for GSCs as they maintained sphere-forming ability and expressed high levels of the NSC markers, SOX2 and Nestin, as reported previously 3 ( Figure 1 ). The GB2 cell line possesses the highest tumorigenic activity among our GSC lines, and we used these cells to perform an unbiased kinome-wide RNAi screen. We transfected GB2 cells that had been maintained in serum-free medium with a library of small interference RNAs (siRNAs) that target each of 704 kinases and kinase-related genes and then measured the expression levels of the stem cell markers CD133 20 and Lgr5. 21 We found 15 kinase genes whose suppression affected CD133 or Lgr5 expression, including 4 kinases known to be involved in the proliferation of GSCs 22 (Table 1 and Supplementary Table S1 ). One of these top 15 genes, ALK was also previously reported to be involved in glioblastomagenesis. 11, 23 However, these studies mainly analyzed the commonly used glioblastoma cell line U87, which does not exhibit any stem-like properties. 3, 24 Furthermore, although U87 cells are highly tumorigenic, U87-derived tumors do not show any glioblastoma-specific features. 3, 24 We therefore set out to study the role of ALK in the tumorigenicity of GSCs. Lentiviral introduction of a short hairpin RNA (shRNA) targeting ALK resulted in a decrease in both sphere formation and stem cell marker expression (Figures 2a and b) . Although the levels of nestin mRNA were downregulated, the levels of Nestin protein did not change drastically, probably due to the stability of the Nestin protein in GB2 cells.
We next examined whether the ALK ligand pleiotrophin is required for the stem-like properties of GSCs. We found that pleiotrophin was expressed at high levels in GB2-5 cells compared with U87 cells and mainly as an 18-kDa protein (Figure 1 ). When pleiotrophin expression was knocked down by shRNA, both sphere formation and expression levels of the stem cell markers examined were suppressed (Figures 2a and b) . We found that GSCs infected with a lentivirus expressing an shRNA targeting ALK or pleiotrophin had increased levels of the neural marker mitogen-activated protein kinase 2 (MAP2; Supplementary Figure S1A ). By contrast, knockdown of either ALK or pleiotrophin resulted in decreased expression of the astrocyte marker glial fibrillary acidic protein (GFAP) and the oligodendrocyte marker Olig2 (Supplementary Figure S1A) . We observed that knockdown of either ALK or pleiotrophin did not cause apoptosis (Supplementary Figure S1B) or any drastic morphological change (Supplementary Figure S1C) . In addition, knockdown of pleiotrophin resulted in a decrease in ALK protein and mRNA levels, suggesting that pleiotrophin stimulates not only ALK kinase activity but also ALK gene expression. These results suggest that ALK and pleiotrophin are important for the selfrenewal and stem-like properties of GSCs.
ALK and pleiotrophin activate the Myc and ESC-like transcriptional programs in GSCs To study the role of the pleiotrophin-ALK axis in GSCs, we investigated the gene expression profiles of GB2 cells in which either ALK or pleiotrophin expression had been suppressed by siRNA. DNA microarray analyses revealed that the MAP kinase, phosphoinositide 3-kinase (PI3-kinase) and Janus kinase/signal transducer and activator of transcription factor (JAK/STAT) pathways are activated in GSCs (Figure 2c and Supplementary  Tables S2-S4 ). Pleiotrophin, but not ALK, was also found to activate the Wnt signaling pathway. We found about a 30% overlap in the genes whose expression was reduced by suppression of ALK and pleiotrophin (Figure 2d and Supplementary Tables S2-S4 ). Furthermore, we found that downstream target genes of ALK and pleiotrophin overlap with those enriched in ESCs, which are known to be overexpressed in poorly differentiated tumors, including glioblastoma 25 ( Figure 2d , upper panel and Supplementary Tables S2-S4). It had been previously reported that the NPM-ALK fusion protein induces Myc expression. 26 We also found that ALK and pleiotrophin target genes overlap those targeted by Myc and its related proteins, the Myc module, which has been reported to account for most of the similarity between ESCs and cancer cells 27 ( Figure 2d , lower panel and Supplementary Tables S2-S4 ). These results suggest that ALK and pleiotrophin may confer a more aggressive oncogenic phenotype to glioblastomas by activating the Myc and ESC-like transcriptional programs.
ALK and pleiotrophin are critical for the tumorigenicity of GSCs It has been suggested that the stem-like properties of GSCs are indispensable for their tumorigenicity. 3, 28 We therefore attempted to clarify the involvement of the pleiotrophin-ALK axis in the tumorigenicity of GSCs. We took GB2 cells containing a Abbreviations: GSC, glioblastoma stem cell; RNAi, RNA interference. Note: Average fold changes in the top 15 genes whose knockdown resulted in the greatest change in CD133 and/or Lgr5 expression. ALK data are indicated in bold and the asterisks indicate genes identified in a similar RNAi screen. 22 The entire results are shown in Supplementary Table S1 .
The pleiotrophin-ALK axis in GSCs R Koyama-Nasu et al lentivirus-delivered shRNA that stably suppresses ALK or pleiotrophin expression and intracranially transplanted these into immunodeficient mice. Mice receiving the ALK-or pleiotrophin-suppressed cells were found to survive longer than those transplanted with GB2 cells infected with a control lentivirus ( Figure 3 ). Histopathological analysis of the tumor xenografts demonstrated that silencing of either ALK or pleiotrophin inhibited glioblastoma progression, whereas control GB2 cells formed invasive glioblastoma (Supplementary Figure S2) . Taken together, these results suggest that the pleiotrophin-ALK axis maintains the tumorigenicity of GSCs.
High expression of pleiotrophin in GSCs Aberrant activation of ALK by oncogenic fusion or mutation can drive tumorigenesis. 7 However, we could not identify any Supplementary Table S4 (hypergeometric P-value).
The pleiotrophin-ALK axis in GSCs R Koyama-Nasu et al mutation in the ALK gene in GB2 cells, consistent with the results of a comprehensive genome analysis reported previously. 29, 30 It is known that pleiotrophin is highly expressed in GSCs (Figure 1 ). We therefore examined the transcriptional control of pleiotrophin in GSCs. We found that pleiotrophin protein and mRNA expression levels decreased during serum-induced differentiation, similar to what was observed for the stem cell markers (Figure 4a ). Moreover, retinoic acid-induced differentiation also resulted in a decrease in the levels of pleiotrophin 31 ( Figure 4b ). We also investigated the expression profiles of pleiotrophin obtained from a public microarray database. 3 Almost all patient glioblastomas and two GSC lines as well as NSCs expressed substantial levels of pleiotrophin (Figure 4c ). By contrast, glioma cell lines and two GSC lines cultured in serum-containing medium expressed relatively low levels of pleiotrophin, presumably because they had undergone 'differentiation'. 3 These results suggest that high expression of pleiotrophin is a common feature of GSCs.
SOX2 directly transactivates the expression of pleiotrophin in GSCs
To further investigate the mechanisms underlying the expression of pleiotrophin, we performed reporter assays using a luciferase reporter under the control of the full-length pleiotrophin 5 0 region ( À 1401 to þ 309) and several deletion variants. When transfected into GB2 cells, a reporter containing the region between À 251 and þ 309 showed a substantial level of activity (Figure 5a , left panel). Furthermore, this activity was repressed upon seruminduced differentiation. We therefore attempted to identify the transcription factor(s) involved in modulating this promoter activity. We first searched the region À 251 and þ 309 for transcription factor consensus binding sites and then compared the expression patterns of the selected transcription factors and pleiotrophin using a microarray database. 3 We found that the expression pattern of pleiotrophin is similar to that of SOX2 (Figure 4c ). Furthermore, a mutant reporter lacking the SOX2-binding site ( À 40 to À 21) showed reduced promoter activity (Figure 5a, right panel) . Chromatin immunoprecipitation analysis demonstrated that endogenous SOX2 was present at the pleiotrophin promoter in GSCs (Figure 5b and Supplementary Figure S3A ). Consistent with these results, silencing of SOX2 by shRNA resulted in a decrease in the levels of pleiotrophin protein and mRNA (Figure 5c and Supplementary Figure S3B) . Similar results were obtained by transfecting two different siRNAs targeting SOX2 (Supplementary Figure S3C) . These results suggest that SOX2 stimulates transcription of the pleiotrophin gene, thereby maintaining high expression levels of pleiotrophin in GSCs.
DISCUSSION
It has been reported that ALK acquires oncogenic potential when truncated and fused to a partner protein, such as NPM, as can occur via chromosomal rearrangement. 7, 8 It has also been reported that ALK is activated by point mutations in its kinase domain in some neuroblastoma.
7,32 Although we could not identify any chromosomal rearrangement or point mutation in ALK in GB2 cells, we found that ALK is highly expressed in GSC lines cultured in serum-free medium, consistent with previous reports. 33 Furthermore, we showed that knockdown of ALK results in a decrease in the self-renewing capacity and tumorigenicity of GB2 cells. We also found that pleiotrophin is overexpressed both in patient glioblastomas and in GSC lines cultured in serum-free medium and that knockdown of pleiotrophin leads to a reduction in the self-renewing capacity and tumorigenicity of GB2 cells. Thus, our results suggest that the pleiotrophin-ALK axis is required for the self-renewal and tumorigenicity of GSCs.
NPM-ALK, the most thoroughly studied ALK-fusion protein, has been reported to signal via the MAP kinase, phospholipase Cg, PI3-kinase and JAK/STAT pathways. 7 Consistent with these reports, our DNA array analysis revealed that the MAP kinase, PI3-kinase and JAK/STAT pathways are activated in GSCs. Furthermore, we found that ALK and pleiotrophin activate the Myc and ESC-like transcriptional programs, which are known to be associated with more aggressive phenotypes in human cancers. 25, 27 Activation of these pathways by ALK has not been previously reported, presumably because earlier studies utilized cultured cell lines grown in serum-containing media that do not exhibit any stem cell-like properties. We found that there was only about a 30% overlap between the genes dependent on ALK and pleiotrophin expression. Furthermore, only pleiotrophin, but not ALK, activated the Wnt signaling pathway. These results appear to be in line with the fact that pleiotrophin signals not only via ALK but also via other receptors, such as RPTPb/z (receptor protein tyrosine phosphatase b/z) and N-syndecan. 34, 35 Interestingly, pleiotrophin is known to stimulate tyrosine phosphorylation of b-catenin through inactivation of RPTPb/z. 34 Furthermore, pleiotrophin stimulates tumor angiogenesis and remodeling of the microenvironment. 36 Consistent with these findings, we found that repression of pleiotrophin has a more dramatic effect on the tumorigenicity of GSCs than repression of ALK.
It has been reported that SOX2 is involved in the tumorigenesis of several cancers, including lung cancer and breast cancer. [37] [38] [39] We found that SOX2 directly transactivates the expression of pleiotrophin in GSCs. Our results appear to be consistent with a previous report showing that knockdown of SOX2 suppresses the tumorigenicity of GSCs in immunodeficient mice. 17 Thus, SOX2-mediated transactivation of pleiotrophin may be important for the tumorigenicity of GSCs. However, knockdown of SOX2 only partially reduced the expression levels of pleiotrophin (Figure 5c and Supplementary Figures 3B and C) , and mutation of the SOX2-binding site in the pleiotrophin promoter only partially reduced activity of a luciferase reporter (Figure 5a, right panel) . In addition, we found that the levels of pleiotrophin decreased faster than those of SOX2 during serum-induced differentiation (Figure 4a ) and that retinoic acid-induced differentiation resulted in a drastic decrease in the expression levels of pleiotrophin but not of SOX2 (Figure 4b) . Thus, the pleiotrophin-ALK axis may be regulated by other transcription factors in addition to SOX2.
SOX2 is well known to have critical roles in the maintenance of neural stem and progenitor cells. 14, 15 For example, it has been reported that multipotent neural stem-like cells transfected with an siRNA targeting SOX2 express increased neurofilaments but decreased GFAP and Nestin levels. 40 These results suggest that SOX2 inhibits the differentiation of neural stem-like cells into neurons and maintains their stem-like properties. Intriguingly, our results appear to be consistent with these results. We found that Figure 3 . ALK and pleiotrophin are critical for the tumorigenicity of GSCs. GB2 cells maintained in serum-free medium were infected with a lentivirus expressing an shRNA-targeting ALK or pleiotrophin. One week after infection, cells were transplanted into the frontal lobe of immunodeficient mice. P-values with comparison to control shRNA by log rank test are shown.
The pleiotrophin-ALK axis in GSCs R Koyama-Nasu et al 3 ). Data obtained with two independent probes for each gene are shown. NBE0308 and NBE1228 are GSC lines. Serum, GSCs cultured in serum-containing medium; IC, intracranial injection; SC, subcutaneous injection.
The pleiotrophin-ALK axis in GSCs R Koyama-Nasu et al Chromatin immunoprecipitation experiments with anti-SOX2 antibody were performed with GB2 cells maintained in serum-free medium. The precipitated chromatin was amplified by quantitative PCR using primers flanking the indicated gene promoters (pleiotrophin and GAPDH) or enhancer (SOX2) (left). The SOX2 enhancer was used as a positive control, as SOX2 has been reported to be autoregulated. 50 The GAPDH promoter was used as a negative control. Control IgG was used as a negative control (right). Error bars represent the s. GSCs infected with a lentivirus expressing an shRNA targeting ALK or pleiotrophin have increased MAP2 but decreased GFAP, Olig2 and Nestin levels. These results suggest that the pleiotrophin-ALK axis inhibits neural differentiation of GSCs but maintains their stem-like characteristics. It would be interesting to examine whether the pleiotrophin-ALK axis is also involved in the maintenance of normal neural stem and progenitor cells. SOX2 has also been reported to have essential roles in the neuronal differentiation of subsets of neural stem and progenitor cells. 14, 15 For example, it has been reported that SOX2 deficiency causes impaired neurogenesis and neurodegeneration in the adult mouse brain. 41, 42 Therefore, it would be interesting to investigate whether the pleiotrophin-ALK axis is also involved in the differentiation of neural stem and progenitor cells.
The ALK inhibitor crizotinib has recently been approved for the treatment of metastatic and late stage ALK-positive NSCLC having translocations of the ALK gene. 9, 10 In addition, the ALK inhibitor TAE684 has been reported to inhibit the growth of ALK-positive ALCL, neuroblastoma and NSCLC cell lines. 43 Thus, we speculate that ALK inhibitors may be effective for the treatment of glioblastoma. ALK has been assumed to have a role in the development and function of the central and peripheral nervous system, as ALK is abundantly expressed in the nervous system during mouse embryogenesis, 7 which could raise concerns about the safety of such therapy. However, both ALK-and pleiotrophinmutant mice survive as long as wild-type mice. 7, 44 In addition, although pleiotrophin is highly expressed in NSCs, it seems dispensable for their proliferation in vivo. 45 Furthermore, it has been reported that the most common adverse reactions of crizotinib are relatively minor, consisting of vision disorder, nausea, diarrhea, vomiting, edema and constipation. 46 Thus, compounds targeting ALK or pleiotrophin would be expected to have relatively few serious side effects due to their effects on NSCs. In addition, we imagine that antibodies or compounds that specifically target the extracellular domain of ALK or pleiotrophin could also hold promise as novel anti-tumor reagents.
MATERIALS AND METHODS

Tumor specimens and primary tumor cultures
Tumor samples classified as primary glioblastoma were obtained from patients undergoing surgical treatment at the University of Tokyo Hospital with informed consent and as approved by the Institutional Review Board. Tumors were washed and mechanically and enzymatically dissociated into single cells. Tumor cells were cultured in Neurobasal medium (Life Technologies, Carlsbad, CA, USA) containing B27 supplement minus vitamin A (Life Technologies), EGF and FGF2 (20 ng/ml each; Wako Pure Chemical Industries, Osaka, Japan). For in vitro differentiation, tumor cells were cultured in DMEM (Dulbecco's modified Eagle's medium)/F-12 medium (Life Technologies) containing 10% fetal bovine serum or 10 mM all-trans retinoic acid (Sigma, St. Louis, MO, USA). U87 and 293FT cells were cultured in DMEM (Nissui, Tokyo, Japan) containing 10% fetal bovine serum. Transfections were performed using Lipofectamine 2000 Reagent, Lipofectamine LTX Reagent or Lipofectamine RNAiMAX Reagent (Life Technologies).
RNAi
Silencer Select Human Extended Druggable Genome siRNA Library was purchased from Life Technologies (the list is given in Supplementary Table S1 ). The siRNA oligonucleotide sequences were as follows: SOX2#1 (5 0 -CAGUAUUUAUCGAGAUAAA-3 0 ), and SOX2#2 (5 0 -AGUG GAAACUUUUGUCGGA-3 0 ). The shRNA oligonucleotide sequences were as follows:
Quantitative RT-PCR Total RNA was extracted using the NucleoSpin RNA Clean-up kit (Takara Bio Inc., Shiga, Japan) and reverse-transcribed into cDNA using PrimeScript RT Master Mix (Takara Bio Inc.). Real-time PCR was performed using LightCycler480 SYBR Green I Master and a LightCycler480 Instrument (Roche, Indianapolis, IN, USA). The results were normalized with the detected value for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or hypoxanthine phosphoribosyltransferase 1 (HPRT1). Primers used in real-time PCR were as follows: 
Immunoblotting
Cells were lysed in lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM DTT, 1 mM EDTA, 2 mM Na 3 VO 4 , 10 mM NaF and protease inhibitors. Lysates were fractionated by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and transferred to a PVDF (polyvinylidene difluoride) membrane (Immobilon-P, Millipore). The membrane was subjected to immunoblot analysis using alkaline phosphatase-conjugated anti-mouse immunoglobulin G (IgG) or anti-rabbit IgG (Promega, Madison, WI, USA) as secondary antibodies. Visualization was performed using the NBT/BCIP colorimetric substrate system (Promega).
Lentivirus production
A lentiviral vector (CS-Rfa-CG) expressing an shRNA driven by the H1 promoter was transfected together with the packaging vectors pCAG-HIVgp and pCMV-VSV-G-RSV-Rev into 293FT cells. All plasmids were kindly provided by H. Miyoshi (RIKEN BioResource Center, Ibaraki, Japan). Virus supernatant was purified by ultracentrifugation at 25 000 r.p.m. for 90 min (SW28 rotor, Beckman Coulter, Brea, CA, USA). Infection efficiency was monitored by GFP expression driven by the CMV promoter.
Intracranial xenograft
One week after lentivirus infection, 1 Â 10 4 cells were injected stereotactically into the right frontal lobe of 5-week-old nude mice (BALB/cAJclnu/nu, CLEA Japn Inc., Tokyo, Japan), following administration of general anesthesia (n ¼ 3 or 4). The injection coordinates were 2 mm to the right of the midline, 1 mm anterior to the coronal suture and 3 mm deep. Mice were monitored for 6 months. Survival of mice was evaluated by KaplanMeier analysis. P-values were calculated using log rank test. The distribution of tumor cells was analyzed by GFP immunostaining. Tumors were histologically analyzed after hematoxylin and eosin staining. All animal experimental protocols were performed in accordance with the guidelines of the Animal Ethics Committee of the University of Tokyo.
Immunohistochemistry
Three months after injection of cells, brains were fixed in 3.7% buffered formalin, dehydrated and embedded in paraffin. Sections (6 mm) were rehydrated, and endogenous peroxidases were blocked by incubation in
The pleiotrophin-ALK axis in GSCs0.3% H 2 O 2 for 5 min. The primary antibody was detected using the VECTASTAIN ABC kit (Vector Laboratories, Burlingame, CA, USA). Slides were lightly counterstained with hematoxylin.
Flow cytometry
Cells were trypsinized, fixed in 70% ethanol and then stained with propidium iodide (Sigma). Cells were passed through a FACSCalibur instrument (BD Biosciences, Billerica, MA, USA).
Microarray analysis
Expression data of cells infected with a lentivirus expressing an shRNA targeting ALK or pleiotrophin were generated using HG-U133 plus 2.0 GeneChips (Affymetrix, Santa Clara, CA, USA). Normalization and analysis of the data were conducted using Gene Spring version 11.5.1 (Agilent Technologies, Santa Clara, CA, USA). Affimetrix CEL files were uploaded to GeneSpring, and RobustMulti-Array normalization was performed. Genes downregulated 41.9-fold by ALK knockdown and those downregulated 42.3-fold by pleiotrophin knockdown were termed 'ALK_signature (ALKsig)' and 'pleiotrophin (PTN) signature (PTN-sig)' genes, respectively (the gene lists are provided in Supplementary Tables S2 and S3 ). BENPOR-ATH_ES_1 were taken from the Molecular Signature Database (MSigDB). 25, 47 The Kim_Myc_module was taken from Myc human module listed in Supplementary Table S3 of Kim et al. 27 The significance of the overlap between sh-ALK, sh-PTN#1, BENPORATH_ES_1 and/or Kim_Myc_module was calculated by the hypergeometric distribution shown in Supplementary Table S4 (Tavazoie et al. 48 ) Functional characterization of these genes was performed using SPEED. 49 The data derived from microarray analysis has been deposited in the Gene Expression Omnibus database (GSE32482). The expression profiles of pleiotrophin and SOX2 in patient glioblastomas, two GSC lines and glioma cell lines were taken from GSE4536 (Lee et al.
3 ).
Reporter assay
Cells were transfected with a luciferase-reporter plasmid. For in vitro differentiation, fetal bovine serum was added to culture medium at a final concentration of 20% and cultured for an additional 24 h. Cells were lysed and firefly luciferase activity was measured with the Luciferase Reporter Assay System (Promega) and shown as the average of three measurements.
Chromatin immunoprecipitation
Cells were fixed with 1% formalin and then the reaction was stopped by the addition of glycine to a final concentration of 125 mM. Cells were lysed in chromatin immunoprecipitated lysis buffer (50 mM Tris-HCl, pH 8.0, 1% SDS, 10 mM EDTA and protease inhibitors). Lysates were sonicated to generate DNA fragments of B1 kb in length and then diluted 10-fold to reduce the concentration of SDS to 0.1%. Immunoprecipitations were performed with an anti-SOX2 antibody. Samples were washed, reversecrosslinked and digested by proteinase K. Purified DNA samples were analyzed by real-time PCR, and differences in the DNA content between the bound and input fractions were determined. Primers used for amplification of the gene promoters or enhancer were as follows: pleiotrophin forward (5 0 -CAGCTCTCGAGTGCAAAGC-3 0 ), pleiotrophin reverse (5 0 -AATGGGAGGGATGAGAGGAG-3 0 ); GAPDH forward (5 0 -TGCGTGCCCAGTT GAACCAG-3 0 ), GAPDH reverse (5 0 -AACAGGAGGAGCAGAGAGCGAAGC-3 0 ); SOX2 forward (5 0 -TGAAGACAGTCTAGTGGGAGATGT-3 0 ), and SOX2 reverse (5 0 -CTCTTTGGCCCAGGAAACT-3 0 ).
